186 related articles for article (PubMed ID: 9723307)
21. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK
Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743
[TBL] [Abstract][Full Text] [Related]
22. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
[No Abstract] [Full Text] [Related]
23. Neoral in liver transplantation.
Jamieson NV; Tan L; Jamieson I; Trull A; Gimson AE; Alexander G; Friend PJ; Calne RY
Transplant Proc; 1996 Aug; 28(4):2229-31. PubMed ID: 8769207
[No Abstract] [Full Text] [Related]
24. Metabolic findings after liver transplantation within a randomised trial with or without steroids.
Tisone G; Angelico M; Vennarecci G; Palmieri G; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Jun; 30(4):1447-8. PubMed ID: 9636587
[No Abstract] [Full Text] [Related]
25. Outcome of liver transplantation after acute rejection and sepsis.
Avolio AW; Agnes S; Chirico AS; Citterio F; Montemagno S; Castagneto M
Transplant Proc; 1998 Dec; 30(8):3962-6. PubMed ID: 9865263
[No Abstract] [Full Text] [Related]
26. NOF-11: a one-year randomized double-blind comparison of Neoral versus Sandimmune in pediatric liver transplantation.
Alvarez F; Atkison P; Grant D; Jones A; Kim P; Kneteman N; Laurin L; Martin S; Paradis K; Shapiro J; Smith L; Superina R; Tan A
Transplant Proc; 1998 Aug; 30(5):1961. PubMed ID: 9723352
[No Abstract] [Full Text] [Related]
27. Neoral is superior to FK 506 in liver transplantation.
Levy GA
Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293
[No Abstract] [Full Text] [Related]
28. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection.
Kato T; Ruiz P; DeFaria W; Weppler D; Khan F; Pinna A; Nery J; Tzakis A
Transplant Proc; 1999; 31(1-2):396. PubMed ID: 10083158
[No Abstract] [Full Text] [Related]
29. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Aug; 30(5):1830-2. PubMed ID: 9723299
[TBL] [Abstract][Full Text] [Related]
30. Does initial graft function influence the outcome after liver transplantation?
Mueller AR; Platz KP; Krause P; Neuhaus R; Lobeck H; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1464-5. PubMed ID: 9636594
[No Abstract] [Full Text] [Related]
31. Conversion from Sandimmune to Neoral in stable liver graft recipients.
Pollard SG; Lodge JP
Transplant Proc; 1996 Aug; 28(4):2244-6. PubMed ID: 8769213
[No Abstract] [Full Text] [Related]
32. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients.
Lagget M; Marzano A; Actis GC; Leone N; Ciancio A; Salizzoni M; Rizzetto M
Transplant Proc; 1998 Aug; 30(5):1863-4. PubMed ID: 9723312
[No Abstract] [Full Text] [Related]
33. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
[No Abstract] [Full Text] [Related]
34. Analysis of long-term results in kidney transplantation performed using a rejection-free protocol with cyclosporine and thoracic duct drainage.
Kinukawa T; Ono Y; Takeuchi N; Hattori R; Ohshima S
Transplant Proc; 1997; 29(1-2):946-7. PubMed ID: 9123600
[No Abstract] [Full Text] [Related]
35. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
36. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
Levy GA
Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
[No Abstract] [Full Text] [Related]
37. [Value of a powerful initial immunosuppression after liver transplantation. Prospective study of 60 cases].
Cherqui D; Duvoux C; Charlotte F; Humeres R; Lauzet JY; Métreau JM; Salvat A; Rotman N; Julien M; Fagniez PL
Gastroenterol Clin Biol; 1994; 18(2):115-22. PubMed ID: 8013792
[TBL] [Abstract][Full Text] [Related]
38. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
Lodge JP; Pollard SG
Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
[No Abstract] [Full Text] [Related]
39. Combined liver-kidney transplantation: long-term follow-up in 18 patients.
Lang M; Kahl A; Bechstein WO; Neumann U; Settmacher U; Frei U; Neuhaus P
Transplant Proc; 1998 Aug; 30(5):1865-7. PubMed ID: 9723313
[No Abstract] [Full Text] [Related]
40. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
